	US 11,981,739 B2
	Chimeric antigen receptor specific for interleukin-23 receptor
Tobias Abel, Antibes (FR); Julie Gertner-Dardenne, Grasse (FR); and François Meyer, Porrentruy (CH)
Assigned to SANGAMO THERAPEUTICS FRANCE, Valbonne Sophia Antipolis (FR)
Appl. No. 17/047,232
Filed by SANGAMO THERAPEUTICS FRANCE, Valbonne Sophia Antipolis (FR)
PCT Filed Apr. 15, 2019, PCT No. PCT/EP2019/059590 § 371(c)(1), (2) Date Oct. 13, 2020, PCT Pub. No. WO2019/197678, PCT Pub. Date Oct. 17, 2019.
Claims priority of provisional application 62/657,233, filed on Apr. 13, 2018.
Prior Publication US 2021/0380704 A1, Dec. 9, 2021
Int. Cl. C07K 14/705 (2006.01); A61K 35/17 (2015.01); A61P 17/00 (2006.01); A61P 29/00 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01); C12N 5/0783 (2010.01)

CPC C07K 16/2866 (2013.01) [A61K 35/17 (2013.01); A61P 17/00 (2018.01); A61P 29/00 (2018.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70578 (2013.01); C12N 5/0637 (2013.01); C07K 2317/622 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/33 (2013.01); C12N 2510/00 (2013.01)]

20 Claims

1. A chimeric antigen receptor (CAR) specific for at least one IL-23 receptor (IL-23R), wherein said CAR comprises:

i) an extracellular binding domain, wherein said binding domain binds to said IL-23R,

ii) optionally an extracellular hinge domain,

iii) a transmembrane domain,

iv) an intracellular signaling domain, and,

v) optionally a tag and/or a leader sequence.